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ABSTRACT 
Sebum production was measured on the fore heads of 21 patients with Park inson's di sease 
before and during long-term L-dopa treatmen t. A stati stica ll y s ignificant decrease in th e 
amount of sebum was demonstrab le during t reatment a lt hough considerable variat ion in 
responsiveness was observed. No correlat ion between the dose of L-dopa and t he degree of 
sebaceous gland inhib ition could be establis hed . The quantitative reduction of sebum could 
not be re lated to t he degree of neurologic improvement. 
Marked seborrhea and seborrheic dermatit is 
occur fr~quently in patients with Parkinson 's 
disease. Sebaceous gland secret ion, when mea-
sured quantitatively, is significan t ly high er in 
both men a nd women with parkinsonism, as 
compared to age- m atched normal subjects [1]. 
The cause of this increased sebaceous gland ac-
tivity is not kn own. 
Many of t he reports on t he use of L-dopa 
(dihydroxyp heny la lanine) for the treatment of 
Parkinso n 's disease have included the observation 
that there is clinical improvement of t he sebor-
rhea (2-8 ]. Two groups of workers have furt her 
reported t hat L-dopa produces a s ignificant quan-
t itative decrease in se bum production in patients 
with parkinsonis m (9 , 10], a lthough another group 
has fai led to confirm this sebum-suppressive ef-
fect [11]. In each of the reports, however , fewer 
than 10 patients were studied. 
The potentia l importance of establis hing a rela -
t ionship between L -dopa and se baceous gland 
secretion is severalfo ld : (1) information m ight be 
obtained on the possible neurohumoral con t rol of 
se baceous gland activity; (2) sebaceous gland 
measurements might be useful as a quantitative 
m arker for monitoring neurologic responsiveness 
to treatment with t he dru g; a nd (3) L-dopa or 
similar drugs might be used in the treatment of 
other di sorders such as acne characteriz ed by 
hypersecretion of sebum . 
METHODS AND MATERIALS 
Twenty-one patients with Parkinson's disease were 
studied. There were 15 men and 6 women, aged 44- 73 
years (mean, 61 years), in whom the disease had been 
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present for 2 to 25 yea rs (mean , 8 years) . 
Sebum production was measured on the forehead 
before and during L-dopa treatment by a method 
described previously [12 ]. In each pat ient , 2 to 5 sebum 
production tests were performed prior to L-dopa treat-
ment. During the period of drug administration which 
varied from 25 to 57 weeks (average, 42 weeks) : 3 to 5 
sebum tests were carried out in each patient at periodic 
in terva ls. The maximu m dose of L-dopa received by 
each ranged from 2.0 to 7.5 grams daily. 
RESULTS 
Table I shows t he effect of L -dopa administra-
tion on t he quantitative change in sebum produc-
t ion in the 21 patients studied . T he statistical 
m ethod of ana lysis was a paired data comparison 
made with use of t he Student's t -test (t = mean 
r!ifference/standard error). A statistically s ignifi-
cant decrease in t he amou nt of sebum was demon-
strable (p < .02 > .01) , a lt hough it is evident that 
the response was quite variable from patient to 
patient and that only in a minority of instances 
did suppression approach or exceed 0.5 m o- of 
sebum . T he ti me-onset of the reduction in sebu m 
co uld not be determined with certain ty since the 
pa tients were not tested at identical intervals 
after treatment was begun . Nonetheless, in 4 
patients (#3, 4, 5, 6) among those who subse-
quently exhibited cons istent lowering of t heir 
surface sebum, t he ini t ia l treatmen t sebum level 
ha d a lready fa llen at 3, 4, 7, and 5 weeks 
r~spective l y. A fur t her decrease in se bum produc~ 
twn was usu a lly observed , bu t in a few other 
individua ls sebaceous inhibi t ion did not appear 
until a fter 2 or 3 mon ths of treatment. There wa 
no further decrease in sebum levels beyond the 
24th wee k of treatment (Table II) . 
No correlation could be established between the 
dose of L-dopa and t he de gree of sebaceous aJand 
inhibit ion (Table I). ln 7 patien ts (#4, 5, 9, 10, 11, 
15, 17) though, se bum production levels, which 
were suppressed by L-dopa , rose part ia lly or 
completely to base line va lues in the 5th and 7th 
m on t h of treatm ent, at a t ime when t he d ose of 
L-dopa was being lowered beca use of side effects. 
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Pa-
tient 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
Mean 
TABLE 1 
Effect of L-dopa on sebum production 
Maximum 
Age Sex 
L-dopa 
Dose 
(g m/day) 
61 M 2.5 
53 F 3.0 
51 M 5.5 
60 M 4.5 
71 F 2.0 
58 F 3.0 
63 F 4.0 
73 M 4.0 
63 M 5.5 
66 M 2.0 
67 F 2.5 
51 M 5.0 
56 M 3.5 
44 M 7.0 
56 F 3.0 
62 M 4.5 
71 M 3.5 
61 M 7.5 
70 M 2.0 
62 M 4.0 
61 M 4.fi 
Sebum Product ion 
(mg/10 cm '/:.l hr) 
Pre-
treat- Treat- Differ-
ment ment ence 
4.25 2.18* - 2.07 
5.00 3.33 - 1.67 
6.28 4.77 - 1.51 
5. 13 4.39 - 0.74 
2.23 1.74 - 0.49 
3.20 2.74 - 0.46 
1.19 0.74 - 0.45 
2.88 2.44 - 0.44 
1.92 1.49 - 0.43 
2.48 2.17 - 0.31 
0.61 0.38 - 0.25 
3.22 2.98 - 0.24 
5.80 5.56 - 0.24 
3.80 3.63 - 0.17 
0.41 0.32 - 0.09 
3.88 3.79 - 0.09 
1.92 1.96 + 0.04 
2.59 2.70 + 0.11 
3.42 3.61 + 0.19 
4.07 4.58 + 0.51 
2.5fl 3.35 + 0.79 
3.18 I 2.so I - 0 .38 
P < .02, > .01 
• average of all tests during L-dopa treatment 
St.tch an association was not consistently ob-
served since one patient (#8) demonstrated a rise 
withoU:t a dose change, and 3 pati~nts (#1 , 2, 3) 
[ailed to show a release of sebum inhibi t ion 
desp ite a reduction i~ L-dopa ~osage. 
A positive correlatiOn was ev1dent between the 
pretreatment sebum level and t he degree of seba-
ceous g l and suppression, but the relat ionship was 
of a low order (r + .42, p = .05). There was no 
correlation between the quantitative sebaceous 
gland response and the patients' ages or duration 
of disease . Most patients were taking one or more 
antipark insoni an drugs together with L-dopa , but 
these had no discernible influen ce on t he effect of 
L-dopa on · sebaceous gland secretion . 
The sebaceous glands of female patients ap-
peared more sensitive to t he effect of L-dopa. 
Despite lower average pretreatment se bum va lues 
as compared to t he men-2.11 vs 3.61 mg-the 
amount of sebum reduction was nearly tw ice as 
great (0.57 .vs 0 .31 mg). However, t here were 
comparatively too few women to allow for statis-
tical validation on this point. 
Of interest was whether a correlation ex isted 
between t he suppression of sebum and the neuro-
logic res ponse in t hese patients, particularly s ince 
the sebaceous gland response differed markedly 
from individu al to individual. In 13 patients 
studied at one instit ut ion, neurologic eva luation 
was based on a function al scale with 3 major 
categori es: 
I bed and chair ex istence 
II partially ambulatory 
III fully ambulatory 
Sub-ratings (m inus sign, no sign, or plus sign) 
were added to differentiate patients within each 
category: 
- most severe 
+ least severe 
TABLE II 
Sebum production and duration of L-dopa treatment 
Pretreatment 
During treatment 
< 24 weeks 
> 24 weeks 
Sebum Production 
(mg/ 10 em'/::! hr) 
3.18 
2.74 
2.88 
TAB LE III 
Comparison of sebum production and neurologic 
response from L -dopa treatment 
Sebum Clinicll l Performance Testing* Evaluat ion 
Pa- (a) (b) (c ) (d) 
tient Differ- (Pre- (Treat- Ergo- Sen- Rigid- Walking 
ence treat- tencet 
(mg) ment ) ment) grapht Length ityt T imet (units) (em) (0- 4) (sees.) 
1 - 2.07 III - Ill 
2 - 1.67 49 1.8 3.8 2. 1 
3 - 1.51 l04 1.6 2.5 1. 2 
4 - 0.74 · II - III 
5 - 0.49 22 - 0.3 - 0.1 - 0.5 
6 - 0.46 I + II 
7 - 0.45 II - III -
8 - 0.44 38 10.2 3.6 16.1 
9 - 0.43 86 - 0.6 0.0 1.7 
10 - 0.31 31 - 1.3 - 0.5 - 0.4 
11 - 0.25 35 0.8 - 0.7 1.5 
12 - 0.24 Ill - III 
13 - 0.24 II III 
14 - 0. 17 lll - III + 
15 - 0.09 III - III 
16 - 0.09 II - III 
17 + 0.04 II - !I 
18 + 0. 11 If + III 
19 + 0.19 28 0.0 3.3 0.1 
20 + 0.51 III - Ill 
21 + 0.79 m- III 
*See text for deta ils 
j" For a and b: average of treatment minus pretreat-
ment values 
For c and d: average of pretreatment minus treat-
ment values 
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In 8 pat ients at another instit ution , evaluation 
included the results of 4 performance tests: (a) 
ergograph-t he work accomplished in squeezi ng a 
rubber bulb for 30 seconds, recorded in arbitrary 
units; (.b) sen tence length-the length , in centi-
meters, of writ ing a standard sentence; (c) 
rigidity-0 (none) to 4 (severe); a nd (d) walking 
time-the time, in seconds, taken to wa lk 20 feet. 
Table III compares the se baceous gland and 
neurologic responses from long-term L-dopa ad-
ministration . Nearly a ll the patien ts were bene-
fited by L-dopa treatment, but it was not possible 
to correlate t he degree of t his improvemen t, as 
evidenced by clinical assessment or by t he motor 
test performances, with t he quant itative reduc-
tion of sebum output . Only t he ergograp h test 
results suggested anything but a random associa-
tion, but even this was not statistica lly s ignificant 
(r + .56, p > 0.1) 
DISCUSSION 
The resu lts of the present study indicate t hat 
L-dopa can reduce sebaceous gla nd secretion in 
Parkinson 's disease. T he vari able effect of L -dopa 
on sebum observed from individual to individual 
affords a probable explana tion for t he apparently 
contradictory findings of previous investigators 
who studi ed only small numbers of patients 
(9- 11]. 
As only a few of our patients showed a substan-
t ial reduction in sebum from L -dopa, i t may seem 
difficult to reconci le this observation with the 
clinical reports of improvement of seborrhea in 
most cases . Since t he appearance of oiliness, 
however, is contributed to s ignificantly , and quite 
likely predominantly, by the degree of skin surface 
moisture [13 ], it is conceivab le that L-dopa may 
affect sweat secretion . T o our knowledge, t his 
aspect has n ot received study . Quite clearly, 
however, our observations indicate that a s ignifi-
cant reduction in sebum is not a regular accom-
paniment to t he neurologic response from L -dopa 
and t hat t he d egree of cha nge in both is essentia lly 
unrelated . It is noteworthy t hat Gli ck et a l re-
ported that while seborrheic dermatitis was im -
proved in 70 percent of patients receiving L-dopa, 
no corre lation could be statistically established 
with neurologic improvement which , nonetheless, 
occurred in nearly 90 percent of the pat ients (14 ]. 
The s ite of action of t he sebum-suppressive 
effect of L-dopa is unkn own. It is tempting to 
speculate that dopamine normally exer ts an in -
hibi tory influence on sebaceous gland secretion , 
but the lack of a more consistent lower ing effect of 
L -dopa on sebum produ ction in patients with 
parkinsonism is disturbing. Direct se baceous 
gland suppression is an unlikely explanation, 
s ince patients wit h acne, in whom sebaceous 
gland secretion is a lso usually elevated , show no 
reduction in sebum from L-dopa [15] . Other 
possibilities include inhibi tion of the testis, adre-
nal, or pitui tary glands resul t ing in diminished 
stimulation of t he androgen -sensitive sebaceous 
gland , but t here is much eviden ce in man that 
1-dopa has no effec t on the pi t uitary- gonadal or 
pituita ry- adrenal axes [16- 19] . 
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